Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer

Atsushi Okita, Toshiaki Saeki, Kenjiro Aogr, Shozo Osumi, Shigemitsu Takashima, Riki Okita, Naruto Taira, Tomokazu Kakishita, Akira Kurita

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m 2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7%. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted.

Original languageEnglish
Pages (from-to)187-194
Number of pages8
JournalActa Medica Okayama
Volume63
Issue number4
Publication statusPublished - Sep 2009

Fingerprint

Toremifene
Paclitaxel
Breast Neoplasms
Toxicity
Treatment Failure
Glycoproteins
Febrile Neutropenia
Chemotherapy
Leukopenia
Drug Resistance
Appointments and Schedules
Therapeutics
Clinical Trials
Safety
Drug Therapy
Pharmaceutical Preparations
Neoplasms

Keywords

  • Metastatic breast cancer
  • P-glycoprotein
  • Paclitaxel
  • Toremifene

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Okita, A., Saeki, T., Aogr, K., Osumi, S., Takashima, S., Okita, R., ... Kurita, A. (2009). Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. Acta Medica Okayama, 63(4), 187-194.

Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. / Okita, Atsushi; Saeki, Toshiaki; Aogr, Kenjiro; Osumi, Shozo; Takashima, Shigemitsu; Okita, Riki; Taira, Naruto; Kakishita, Tomokazu; Kurita, Akira.

In: Acta Medica Okayama, Vol. 63, No. 4, 09.2009, p. 187-194.

Research output: Contribution to journalArticle

Okita, A, Saeki, T, Aogr, K, Osumi, S, Takashima, S, Okita, R, Taira, N, Kakishita, T & Kurita, A 2009, 'Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer', Acta Medica Okayama, vol. 63, no. 4, pp. 187-194.
Okita, Atsushi ; Saeki, Toshiaki ; Aogr, Kenjiro ; Osumi, Shozo ; Takashima, Shigemitsu ; Okita, Riki ; Taira, Naruto ; Kakishita, Tomokazu ; Kurita, Akira. / Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer. In: Acta Medica Okayama. 2009 ; Vol. 63, No. 4. pp. 187-194.
@article{56f487591fe14b13aa54cae2ccbbd9d9,
title = "Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer",
abstract = "Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m 2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7{\%}. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted.",
keywords = "Metastatic breast cancer, P-glycoprotein, Paclitaxel, Toremifene",
author = "Atsushi Okita and Toshiaki Saeki and Kenjiro Aogr and Shozo Osumi and Shigemitsu Takashima and Riki Okita and Naruto Taira and Tomokazu Kakishita and Akira Kurita",
year = "2009",
month = "9",
language = "English",
volume = "63",
pages = "187--194",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer

AU - Okita, Atsushi

AU - Saeki, Toshiaki

AU - Aogr, Kenjiro

AU - Osumi, Shozo

AU - Takashima, Shigemitsu

AU - Okita, Riki

AU - Taira, Naruto

AU - Kakishita, Tomokazu

AU - Kurita, Akira

PY - 2009/9

Y1 - 2009/9

N2 - Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m 2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7%. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted.

AB - Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m 2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7%. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted.

KW - Metastatic breast cancer

KW - P-glycoprotein

KW - Paclitaxel

KW - Toremifene

UR - http://www.scopus.com/inward/record.url?scp=70349330669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349330669&partnerID=8YFLogxK

M3 - Article

C2 - 19727203

AN - SCOPUS:70349330669

VL - 63

SP - 187

EP - 194

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -